IL245672A0 - פירימידופירימידינונים המשמשים כמעכבי קינאז wee-1 - Google Patents

פירימידופירימידינונים המשמשים כמעכבי קינאז wee-1

Info

Publication number
IL245672A0
IL245672A0 IL245672A IL24567216A IL245672A0 IL 245672 A0 IL245672 A0 IL 245672A0 IL 245672 A IL245672 A IL 245672A IL 24567216 A IL24567216 A IL 24567216A IL 245672 A0 IL245672 A0 IL 245672A0
Authority
IL
Israel
Prior art keywords
pyrimidopyrimidinones
wee
useful
kinase inhibitors
kinase
Prior art date
Application number
IL245672A
Other languages
English (en)
Other versions
IL245672B (he
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of IL245672A0 publication Critical patent/IL245672A0/he
Publication of IL245672B publication Critical patent/IL245672B/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL245672A 2013-12-19 2016-05-17 פירימידופירימידינונים המשמשים כמעכבי קינאז wee–1 IL245672B (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (2)

Publication Number Publication Date
IL245672A0 true IL245672A0 (he) 2016-06-30
IL245672B IL245672B (he) 2021-10-31

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245672A IL245672B (he) 2013-12-19 2016-05-17 פירימידופירימידינונים המשמשים כמעכבי קינאז wee–1

Country Status (28)

Country Link
US (1) US9850247B2 (he)
EP (1) EP3083625B1 (he)
JP (1) JP6437559B2 (he)
KR (1) KR102405462B1 (he)
CN (1) CN105829315B (he)
AU (1) AU2014369457B2 (he)
BR (1) BR112016014151B1 (he)
CA (1) CA2933755C (he)
CY (1) CY1120035T1 (he)
DK (1) DK3083625T3 (he)
ES (1) ES2650013T3 (he)
GB (1) GB201322602D0 (he)
HR (1) HRP20180080T1 (he)
HU (1) HUE037908T2 (he)
IL (1) IL245672B (he)
LT (1) LT3083625T (he)
MX (1) MX371108B (he)
NO (1) NO3083625T3 (he)
NZ (1) NZ720178A (he)
PL (1) PL3083625T3 (he)
PT (1) PT3083625T (he)
RS (1) RS56731B1 (he)
RU (1) RU2691105C1 (he)
SG (1) SG11201603814TA (he)
SI (1) SI3083625T1 (he)
SM (1) SMT201800020T1 (he)
WO (1) WO2015092431A1 (he)
ZA (1) ZA201603337B (he)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137593B (zh) * 2015-04-21 2021-01-05 上海交通大学医学院附属瑞金医院 蛋白激酶抑制剂的制备和用途
CA3003737C (en) 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
EP3543242B1 (en) * 2016-11-16 2024-01-03 Impact Therapeutics (Shanghai), Inc 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6h)-ketone compound
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
WO2018133829A1 (zh) * 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
MX2019011506A (es) 2017-03-31 2019-11-01 Seattle Genetics Inc Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
WO2019011228A1 (zh) * 2017-07-10 2019-01-17 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
JP7290638B2 (ja) 2017-11-01 2023-06-13 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Wee1阻害剤としての大環状化合物及びその使用
CA3088997A1 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
KR20210066839A (ko) * 2018-09-27 2021-06-07 베타 파머수티컬 컴퍼니 리미티드 Fgfr4 저해제 및 그것의 용도
EP3875460A4 (en) 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CN113614087B (zh) 2019-03-22 2023-06-02 首药控股(北京)股份有限公司 Wee1抑制剂及其制备和用途
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
US20220168313A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
PT3964510T (pt) 2019-04-30 2024-07-29 Wuxi Biocity Biopharmaceutics Co Ltd Forma cristalina do composto inibidor de wee1 e sua utilização
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2021254389A1 (zh) 2020-06-17 2021-12-23 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
EP4221710A4 (en) * 2020-10-01 2024-09-18 University of Washington DRUG-LIKE MOLECULES AND METHODS FOR THERAPEUTIC TARGETING OF MICRORNA-21
TW202239409A (zh) * 2020-12-18 2022-10-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
EP4262978A1 (en) * 2020-12-18 2023-10-25 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases
KR20240004539A (ko) 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도
AU2022297176A1 (en) 2021-06-25 2024-01-04 Korea Research Institute Of Chemical Technology Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制pkmyt1之化合物治療癌症之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
RU2006136082A (ru) 2004-03-15 2008-04-27 Ф.Хоффманн-Ля Рош Аг (Ch) Новые производныедихлорфенилпиридо[2,3]пиримидина, их получение и применение в качестве фармацевтических агентов
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
EP2155752B1 (en) 2007-04-25 2018-09-19 Merck Sharp & Dohme Corp. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
EP2168966B1 (en) 2007-06-15 2016-09-28 Msd K.K. Bicycloaniline derivative
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
WO2010067888A1 (en) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
AU2009325398A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
CA2820408C (en) * 2010-12-06 2018-03-06 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
EP2731953A1 (en) 2011-07-15 2014-05-21 Abbvie Inc. Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Also Published As

Publication number Publication date
CN105829315A (zh) 2016-08-03
RU2691105C1 (ru) 2019-06-11
SG11201603814TA (en) 2016-07-28
MX371108B (es) 2020-01-17
EP3083625B1 (en) 2017-11-01
US9850247B2 (en) 2017-12-26
PL3083625T3 (pl) 2018-03-30
ZA201603337B (en) 2018-07-25
AU2014369457B2 (en) 2018-08-09
CN105829315B (zh) 2019-03-08
MX2016007801A (es) 2016-09-07
SI3083625T1 (en) 2018-03-30
HRP20180080T1 (hr) 2018-03-09
US20160318936A1 (en) 2016-11-03
DK3083625T3 (en) 2017-12-18
PT3083625T (pt) 2018-02-06
JP6437559B2 (ja) 2018-12-12
RS56731B1 (sr) 2018-03-30
HUE037908T2 (hu) 2018-09-28
KR102405462B1 (ko) 2022-06-03
NZ720178A (en) 2022-05-27
GB201322602D0 (en) 2014-02-05
IL245672B (he) 2021-10-31
KR20160098499A (ko) 2016-08-18
RU2016123363A (ru) 2018-01-25
CA2933755C (en) 2023-01-31
SMT201800020T1 (it) 2018-05-02
LT3083625T (lt) 2017-12-27
WO2015092431A1 (en) 2015-06-25
CY1120035T1 (el) 2018-12-12
CA2933755A1 (en) 2015-06-25
JP2017500335A (ja) 2017-01-05
BR112016014151A2 (he) 2017-08-08
ES2650013T3 (es) 2018-01-16
AU2014369457A1 (en) 2016-06-09
EP3083625A1 (en) 2016-10-26
BR112016014151B1 (pt) 2023-01-17
NO3083625T3 (he) 2018-03-31

Similar Documents

Publication Publication Date Title
ZA201603337B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
LT3057959T (lt) Dnr-pk inhibitoriai
SG11201507203RA (en) Dna-pk inhibitors
IL242453B (he) נגזרות ביפיראזול כמעכבי jak
ZA201506156B (en) Novel inhibitors
GB201307155D0 (en) Kinase inhibitors